gip glp 1 agonist tirzepatide Research Progress on the GIP/GLP‐1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes - Ma - 2023 - Journal of Diabetes Research

Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist

21.00

★★★★☆4.8 (126)

Full article: Tirzepatide, a novel, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist for the ongoing diabesity epidemic: the dawn of a new era?

20.87

★★★★★4.9 (98)

It's important to study the difference in GLP-1 medications.⁣ Our analysis found tirzepatide is associated with a lower risk of serious heart and kidney complications compared to dulaglutide in adults with Type

28.93

★★★★★5.0 (157)

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists

29.16

★★★★★4.7 (84)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology

29.32

★★★★★4.9 (203)

Tirzepatide is redefining obesity & diabetes care. Dual GIP/GLP-1 action → deeper weight loss, stronger metabolic control, and emerging benefits from OSA to cardiometabolic risk. The era of multi-pathway incretin therapy has

22.79

★★★★★5.0 (176)

Semaglutide and #tirzepatide effectively target #GLP1 and GIP receptors for obesity treatment, with future therapies exploring further receptor targeting for improved outcomes. https://ja.ma/4oHQi4J

23.50

★★★★★4.8 (132)